FDA WARNING_LETTER - Gulf Pharmaceutical Industries - Julphar - October 03, 2011

This FDA Warning Letter, dated February 23, 2012, was issued to Gulf Pharmaceutical Industries following an inspection from September 25 to October 3, 2011. The inspection revealed significant Current Good Manufacturing Practice (CGMP) violations, rendering their drug products adulterated under 21 U.S.C. § 351(a)(2)(B). The firm's October 28, 2011, response was deemed insufficient.

Key violations include: 1. **Microbiological Contamination Prevention (21 C.F.R. § 211.113(b)):** * Failure to perform unidirectional airflow pattern studies (smoke studies) for the ampoule filling line (a repeat observation from 2004). * Inadequate unidirectional airflow studies for the vial filling line, showing turbulent airflow. * Deficient HEPA air velocity evaluation, not performed at the working level. * Poor aseptic technique observed during gowning and production. * Deficient revalidation of sterilization cycles for machine parts, lacking documented biological indicator (BI) and thermocouple placements. 2. **Equipment Cleaning and Maintenance (21 CFR § 211.67(a)):** * Lack of data to demonstrate adequate cleaning procedures for non-dedicated equipment, specifically no cleaning validation, verification